Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Withdrawn 1Unknown 1Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3CNS 2Thoracic 1Breast 1

Conditions

Lymphoma, T-Cell, Cutaneous 8Sezary Syndrome 5Mycosis Fungoides 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma, B-Cell, Marginal Zone 5Hodgkin Disease 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Multiple Myeloma 4Lymphoma, T-Cell, Peripheral 4Lymphoma, Non-Hodgkin 4Lymphoma, Mantle-Cell 4Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, Follicular 4Leukemia, Lymphocytic, Chronic, B-Cell 4Burkitt Lymphoma 4Melanoma 3Lymphoma 3Breast Neoplasms 3Waldenstrom Macroglobulinemia 2Vomiting 2Uveal Melanoma 2Testicular Neoplasms 2Primary Myelofibrosis 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Pdgfra-Associated Chronic Eosinophilic Leukemia 2Neuroblastoma 2Neoplasms 2Nausea 2Myeloproliferative Disorders 2Lymphoma, Large-Cell, Anaplastic 2

Interventions

pembrolizumab 300Nivolumab 273Ipilimumab 250aldesleukin 137Cyclophosphamide 135Interleukin-2 105trametinib 82dabrafenib 76Temozolomide 75Dacarbazine 74Vemurafenib 71fludarabine 67fludarabine phosphate 61Biopsy 49binimetinib 47sargramostim 44Radiosurgery 44Bevacizumab 43Paclitaxel 42encorafenib 40incomplete Freund's adjuvant 39atezolizumab 38Radiotherapy 37Cisplatin 36CTLA-4 Antigen 36Carboplatin 35cobimetinib 34Specimen Handling 34Magnetic Resonance Spectroscopy 34Introns 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Melanoma × Dexamethasone × Dermatologic × Clear all
NCT02709889 2020-10-19

Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors

AbbVie

Phase 1/2 Terminated
200 enrolled 21 charts
CNSDermatologic

Glioblastoma, Melanoma, Carcinoma, Medullary

NCT04001725 2019-11-13

OPTIMAL

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase 2 Unknown
110 enrolled
BreastCNSDermatologicThoracic

Brain Neoplasms, Breast Neoplasms, Diabetes Mellitus, Lung Neoplasms, Melanoma, Neoplasms

NCT02862145 2016-09-27

MRX34-102

Mirna Therapeutics, Inc.

Phase 1/2 Withdrawn
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡